替罗非班在急性心肌梗死PCI术后的临床应用

被引：7

作者：

贾晓刚

机构：

[1] 天津市第五中心医院内科

来源：

海南医学 | 2009年 / 02期

关键词：

心肌梗塞; 经皮冠状动脉介入术; 替罗非班; 急诊介入(PCI);

D O I：

暂无

中图分类号：

R542.22 [];

学科分类号：

1002 ; 100201 ;

摘要：

目的观察替罗非班在急性心肌梗死患者急诊介入(PCI)术后的临床应用效果和安全性。方法符合急性心肌梗死入选标准患者82例,随机分为试验组(A=42)和对照组(B=40)。试验组微量泵持续泵入替罗非班,对照组微量泵持续泵入普通肝素。所有患者均口服阿司匹林、氯吡格雷、皮下注射低分子肝素。疗程均为2-3d。观察两组心电图改变、血小板聚集率、主要终点事件(顽固性缺血状态、新近心肌梗死和死亡)及不良反应发生情况。结果与对照组相比,试验组心电图缺血性改变有明显好转(P<0.01);血小板聚集率明显下降(P<0.01);主要终点事件有下降趋势,无严重不良反应。结论替罗非班可快速、完全地阻断血小板聚集,在急诊介入治疗急性心肌梗死患者是安全有效的。

引用

页码：29 / 31

页数：3

共 8 条

[1]

The impact of GPⅡb/Ⅲa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients. Lavi S,Gruberg L,Kapeliovich M,et al. Journal of Invasive Cardiology . 2005

[2]

Different effects of tirofiban and aspirinplus clopidogrel on myocardial no reflow in a mini-swine model of acute myocardial infarction and reperfusion. Yang YJ,Zhao JL,You SJ,et al. Heart . 2006

[3]

Impact of Early Tirofiban Administration on Myocardial Salvage in Patients with Acute Myocardial Infarction Undergoing Infarct-Related Artery Stenting. Emre A,Ucer E,Yesilcimen K,et al. Cardiology . 2006

[4]

Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty im-proves angiographic outcomes:results of the Tirofiban Given in the E-mergency Room before Primary Angioplasty(TIGER-PA)pilot trial. Lee DP,Herity NA,Hiatt BL,et al. Circulation . 2003

[5]

Early vs late admin-istration of glycoproteinⅡb/Ⅲa inhibitors in primary percuta-neous coronary intervention of acute ST-segment elevation my-ocardial infarction:a mete-analysis. Montalescot G,Borentain M,Payot L,et al. The Journal of The American Medical Association . 2004

[6]

Role of abciximab in the treatment of coronary artery disease. Gabriel HM,Oliveira EI. Expert Opinion on Biological Therapy . 2006

[7]

Effect ofTirofiban Therapy on ST Segment Resolution andClinical Outcomes in Patients with ST Segment ElevatedAcute Myocardial Infarcti on Undergoing PrimaryAngioplasty. Uyarel H,Uzunlar B,Unal Dayi S,et al. Cardiology . 2006

[8]

Intravenous glycoproteinⅡb/Ⅲa receptor antagonists reduce mortality after percutaneous coronary interventions. Karvouni E,Katritsis DG,Ioannidis JP. Journal of the American College of Cardiology . 2003

← 1 →